Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal cancer
2023-506703-26-00Phase 3Authorised
- Sponsor
- Institut Jules Bordet
- Start
- Feb 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, capecitabine and folinic acid in rectal adenocarcinoma (2 arms), sponsored by Institut Jules Bordet. Primary endpoints: Net Benefit Treatment, Overall survival at 3 years and 3 more. Planned start Feb 2024; status: authorised.
02
Drugs
oxaliplatinfluorouracilcapecitabinefolinic acid
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2023-506703-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506703-26-00.